Related Experiment Video
Updated: May 21, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Targeted asthma therapies: confirmations, hopes, and disappointments]
1Service de Pneumologie, CHU de Liège, Belgique.
Abstract:
Asthma is a chronic inflammatory disease of the airways. The inflammatory process is driven by different pathways involving cytokines and other protein mediators. Patients with severe asthma are at high risk of severe exacerbations and death and have few therapeutic options available. Therefore, biological agents have been developed to help patients with refractory asthma by interfering with several compounds of the asthma inflammatory cascade. In addition to decreasing exacerbations, some of those treatments have a steroid sparing role and many beneficial effects in asthmatics.
Insights
Severe asthma patients have limited options, but biological agents offer new hope by targeting airway inflammation. These advanced therapies reduce exacerbations and can decrease steroid dependence in difficult-to-treat asthma.
Area of Science:
- Respiratory Medicine
- Immunology
- Pharmacology
Context:
- Asthma is a chronic airway inflammatory disease.
- Severe asthma presents significant risks, including exacerbations and mortality.
- Limited therapeutic options exist for patients with refractory asthma.
Purpose:
- To review the role of biological agents in managing severe, refractory asthma.
- To highlight the mechanisms of action for novel asthma therapies.
- To discuss the benefits of biological agents beyond exacerbation reduction.
Summary:
- Biological agents target specific inflammatory pathways in asthma.
- These therapies interfere with cytokines and protein mediators driving airway inflammation.
- They offer new treatment avenues for patients with severe and refractory asthma.
Impact:
- Biological therapies reduce severe asthma exacerbations.
- Some treatments provide a steroid-sparing effect, minimizing corticosteroid side effects.
- These agents improve overall management and quality of life for asthmatics.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-I: Introduction
